|
Q3 FY2026
As of Aug 30, 2026
|
Q2 FY2026
As of May 31, 2026
|
Q1 FY2026
As of Mar 1, 2026
|
Q4 FY2025
As of Nov 30, 2025
|
Q3 FY2025
As of Aug 31, 2025
|
Q2 FY2025
As of Jun 1, 2025
|
Q1 FY2025
As of Mar 2, 2025
|
Q4 FY2024
As of Dec 1, 2024
|
Q3 FY2024
As of Aug 25, 2024
|
Q2 FY2024
As of May 26, 2024
|
Q1 FY2024
As of Feb 25, 2024
|
Q4 FY2023
As of Nov 26, 2023
|
Q3 FY2023
As of Aug 27, 2023
|
Q2 FY2023
As of May 28, 2023
|
Q1 FY2023
As of Feb 26, 2023
|
Q4 FY2022
As of Nov 27, 2022
|
Q3 FY2022
As of Aug 28, 2022
|
Q2 FY2022
As of May 29, 2022
|
Q1 FY2022
As of Feb 27, 2022
|
Q4 FY2021
As of Nov 28, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments in marketable securities | ||||||||||||||||||||
| Trade receivables, net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Non-current assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued salaries, wages and employee benefits | ||||||||||||||||||||
| Restructuring liabilities | ||||||||||||||||||||
| Accrued income taxes | ||||||||||||||||||||
| Accrued sales returns and allowances | ||||||||||||||||||||
| Short-term operating lease liabilities | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Postretirement medical benefits | ||||||||||||||||||||
| Pension liabilities | ||||||||||||||||||||
| Long-term operating lease liabilities | ||||||||||||||||||||
| Long-term employee related benefits and other liabilities | ||||||||||||||||||||
| Total long-term liabilities held for sale | ||||||||||||||||||||
| Long-term employee related benefits | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Common stock — $0.001 par value; 1,200,000,000 Class A shares authorized, 99,254,572 shares and 103,620,225 shares issued and outstanding as of August 30, 2026 and November 30, 2025, respectively; and 422,000,000 Class B shares authorized, 284,215,167 shares and 286,756,831 shares issued and outstanding, as of August 30, 2026 and November 30, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
